Spyre Therapeutics (SYRE) Accounts Payables (2015 - 2026)

Spyre Therapeutics (SYRE) has 12 years of Accounts Payables data on file, last reported at $5.7 million in Q1 2026.

• Quarterly Accounts Payables rose 54.3% year-over-year to $5.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.7 million (up 54.3% YoY) and the FY2025 annual result came in at $8.9 million, up 1236.94% from the prior year.
• Accounts Payables declined to $5.7 million in Q1 2026, from $8.9 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $8.9 million in Q4 2025 to a low of $666000.0 in Q4 2024.
• A 5-year average of $3.6 million and a median of $3.2 million in 2024 frame the typical range for Accounts Payables.
• Annual changes were most pronounced in 2023 — Accounts Payables slumped 59.84% — and 2025, when it soared 1236.94%.
• Tracing SYRE's Accounts Payables over 5 years: stood at $4.2 million in 2022, then sank by 78.55% to $896000.0 in 2023, then fell by 25.67% to $666000.0 in 2024, then soared by 1236.94% to $8.9 million in 2025, then sank by 36.07% to $5.7 million in 2026.
• The last three Accounts Payables figures came in at $5.7 million (Q1 2026), $8.9 million (Q4 2025), and $7.5 million (Q3 2025), per Business Quant data.